Argus Research Upgrades CVS Caremark to “Buy” (CVS)
Drug store chain CVS Caremark Corporation (CVS) was upgraded by analysts at Argus Research on Wednesday.
The analysts upgraded CVS to “Buy” and see shares reaching $64, up from the previous target of $58. This new target suggests an 11% upside to Tuesday’s closing price of $57.63.
CVS shares were down 27 cents, or -0.47%, during morning trading on Wednesday. The stock is up +18.8% year-to-date.
The Bottom Line
Shares of CVS Caremark Corporation (CVS) have a dividend yield of 1.57% based on Wednesday’s intraday trading price of $57.41 and the company’s annualized dividend payout of 90 cents per share.
CVS Caremark Corporation (CVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability